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Abstract
Alendronate is indicated for treatment of a variety of bone metabolism disorders. In spite of quite low plasma concen-
trations following oral administration, pharmacokinetic study of alendronate based on plasma concentrations had normally
been reported for up to 8 h. Due to much longer detectable periods in urine, a number of pharmacokinetic studies have been
based upon urinary excretion data. The objective of this study was to determine pharmacokinetics of alendronate following
oral administration of combined Alendronate/Vitamin D3 tablet. Blood and urine samples were collected for 10 h after oral
administration of a combined Alendronate/Vitamin D3 tablet to healthy volunteers. Alendronate levels in plasma and urine
samples were determined by high-performance liquid chromatography (HPLC) with fluorescence detection. The analytical
method involved co-precipitation of alendronate in plasma or urine samples with calcium and followed by solid-phase extrac-
tion (SPE) process. Pharmacokinetic parameters were analyzed by the non-compartmental method using WinNonlin. Pharma-
cokinetics parameters, i.e. Cmax, Tmax, AUC0-10, T1/2, were 56.6±11.8 ng/mL, 1.29±0.39 h, 132.4±46.9 ng·h/mL, and 3.43±2.24 h,
respectively. Amount excreted in 10 h urine and maximum excretion rate (Rmax) were 578.59±308.9 µg and 143.3±72.8 µg/h,
respectively. Although these parameters were different from previously reported values, Rmax obtained at 1.29±0.76 h agreed
well with Tmax observed from plasma data. Based upon urinary excretion data, enhanced absorption of alendronate after
administration of a combined Alendronate/Vitamin D3 tablet is suggested.
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1. Introduction
Alendronate (4-amino-1-hydroxybutylidine-1,1-bis-
phosphonate)  is  indicated  for  use  in  a  variety  of  bone
diseases,  including  postmenopausal  osteoporosis,  hyper-
calcemia of malignancy, and Paget’s disease (Hosking et al.,
1998; Fleisch, 1999). Alendronate has a strong affinity for the
solid-phase calcium phosphate of the bone, where it has its
primary action. It is an effective inhibitor of osteoclast and
bone resorption. About 40% of an oral dose was excreted
within  8-12 h,  while  the  remaining  was  gradually  released
from the bone, depending on the rate of bone turnover, and
was eventually eliminated in the urine (Lin, 1996; Porras et
al., 1999). The plasma half-life of alendronate was 1.7-1.8 h
in healthy individuals (Lin, 1996; Porras et al., 1999). Its
terminal half-life of more than 10 years reflects skeletal reten-
tion as reported in postmenopausal women (Khan et al.,
1997).
Alendronate  is  currently  available  in  a  tablet  com-
bined with cholecalciferol (vitamin D3) either 2800 IU or 5600
IU in a once-weekly dose (Fosamax Plus
® D, package insert).
Since low vitamin D level is a common feature among post-
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menopausal women and osteoporotic patients (Moniz et al.,
2005; Gallacher et al., 2005), the extra vitamin D in addition to
dietary sources, can be beneficial to osteoporotic patients.
Although pharmacokinetics of alendronate after oral adminis-
tration of  alendronate plus vitamin D3 tablet based on uri-
nary excretion were recently reported (Denker et al., 2010),
the data based upon plasma levels have not been addressed.
Several plasma or urine pharmacokinetic data have been
revealed  employing  reliable  HPLC-fluorescence  methods
(Ptacek et al., 2002; Roldan et al., 2005; Kang et al., 2006;
Yun et al., 2006; Tarcomnicu et al., 2007; Rhim et al., 2009;
Thudi et al., 2009).
This  study  aims  to  examine  pharmacokinetics  of
alendronate in both human plasma and urine after a single
oral  dose  of  a  tablet  of  combined  Alendronate/Vitamin D3
using a validated HPLC method with fluorescence detection.
2. Material and Methods
2.1 Study designs
Healthy male volunteers aged 18-35 years and body
mass index (BMI) 18-25 kg/m
2 were recruited to the study.
They  were  screened  based  on  medical  history,  physical
examination, and standard laboratory test results (complete
blood count, fasting blood glucose, blood urea nitrogen, bio-
chemical profile, and urinalysis). They were excluded if they
smoked, had a history of alcohol and/or substance abuse, had
an allergic history to alendronate, had used bisphosphonates
(or other structurally similar substance) 4 weeks prior to the
study period, had participated in any clinical studies or were
using any medications within at least 4 weeks prior to this
study. In addition, the volunteers were asked to refrain from
drinking alcohol for at least 1 week prior to and throughout
the study. All participants were informed about the risks and
benefits, and details of the study. Written informed consent
was obtained from all volunteers before any study procedures
were performed. The study was conducted in accordance with
the principles of good clinical practice and was approved by
Ethics Committee, Phramongkutklao College of Medicine and
Phramongkutklao Hospital, Thailand.
2.2 Blood sampling
After an overnight (or at least 10 h) fast, each volun-
teer was administered a combined tablet containing 70 mg
of alendronate sodium and 2,800 IU of vitamin D3 (Fosamax
Plus
®, Merck Sharp & Dome de Mexico; Mexico) orally with
250 mL water. The volunteers continued to fast for 4 h, after
which a standard lunch was served. Approximately 10 mL
of  blood  sample  was  collected  through  a  heparin-locked
indwelling catheter placed in a forearm vein before the dose
and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 h after administra-
tion. The catheter was flushed with 1 mL of heparin in normal
saline solution after each blood sampling. Blood samples were
centrifuged immediately, and plasma samples were frozen at
-20°C until the analysis. Urine samples were collected before
drug administration, and at 0-2, 2-4, 4-8, and 8-10 h after ad-
ministration. After collection, urine samples were monitored
for volume, pH and appearance prior to storage at -20°C until
assayed.
2.3 Preparation of plasma and urine samples
The  analytical  method  for  the  determination  of
alendronate in plasma and urine used in this study was modi-
fied from that reported by Yun et al., 2006. Method modifica-
tions included sample preparation, derivatization conditions,
and chromatographic conditions. The frozen samples were
allowed to thaw at room temperature before processing. Three
mL of the plasma sample was pipetted into a 15-mL polypro-
pylene centrifuge tube, briefly shaked with added 25 mL I.S.
(24 mg/mL pamidronate disodium). Three mL of trichloro-
acetic  acid  (6%)  was  added  to  precipitate  plasma  proteins
during vortex-mixing for 45 sec. The protein precipitate was
sedimented at 4,000 rpm (1,914 g) for 10 min at 10°C. The
supernatant was carefully transferred to a new tube. Then
200 µL of 0.1 M KH2PO4 and the same amount of 0.1 M CaCl2
were added and the tube was briefly shaked for 10 sec. After
subsequent addition of 4.0 M NaOH and shaking for 30 sec,
the solution became cloudy under vortex mixing. The calcium
co-precipitate was collected by centrifugation at 4,000 rpm
(1,914 g) for 10 min at 10°C. After removal of supernatant, the
precipitate was completely dissolved in 0.5 mL of 0.2 M acetic
acid. A repeat precipitation was obtained by gradual addition
of 4.0 M NaOH. The resulting precipitate was finally dissolved
in 1 mL of 0.2 M acetate buffer (pH 6.0) and 40 µL of 0.2 M
acetic acid. Prior to solid phase extraction, the solution was
diluted with 2.0 mL distilled water and 250 µL of 0.2 M EDTA.
Three mL of the sample solution was loaded onto a DEA SPE
cartridge (Bond Elute-DEA, Varian, USA) pre-washed with
water. The cartridge was washed with 1.0 mL distilled water
and  alendronate  was  eluted  with  1.0  mL  of  0.2  M  sodium
citrate. An aliquot of the eluate was taken for the derivatiza-
tion.
The  derivatization  procedure  involved  addition  of
200 µL of 1 M Na2CO3 (pH 11.9) to 540 µL of the sample.
Subsequently, 200 µL of FMOC solution was added and
the  reaction  was  allowed  to  take  place  for  5  min,  at  room
temperature, with constant stirring. The reaction was stopped
by the addition of 20 µL glycine solution (360 mmole/mL) and
200 µL citric acid. One hundred µL of the derivatized solution
was injected into the chromatographic system.
Urine sample was prepared according to the proce-
dures  described  above  for  the  plasma  sample  except  for
protein precipitation step. Each 1 mL of urine was diluted to
5 mL with distilled water prior to sample preparation.
2.4 Tolerability
Adverse events (nausea, vomiting, diarrhea, abdomi-
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joint pain, and fatigue) were monitored via observation and
interview. Vital signs were monitored over 10 h after drug
administration. All other adverse events were recorded on
the clinical record form for up to 1 week after the study.
2.5 Chromatographic conditions
The HPLC system (CTO-10AS VP, Shimadzu, Tokyo,
Japan) consisted of two LC-20AD VP pumps, a RF-10AXL
fluorescence detector, an SIL-10ADVP autosampler, an SCL-
10AVP controller, and a DGE-14A degassing unit. Separation
was performed on a C18 column (Vertisep
 GES 150 mm x
4.6 mm i.d., 5 mm). The detector operated with an excitation
wavelength of 260 nm and an emission wavelength of 310 nm.
The mobile phase consisted of a mixture of an organic
part (acetonitrile: methanol = 50: 50 v/v, solvent A), and a
buffer  solution  (25  mM  citric  acid:  25  mM  sodium  pyro-
phosphate buffer  pH 4.3, solvent B). Gradient elution was
performed by increasing the percentage of the organic part
from 32% to 60% (solvent A), as follows: 32: 68 at 0-17 min;
60: 40 at 17-22 min; and 32: 68 at 22-40 min. The condition
was operated at 35°C with a constant flow rate of 1.5 mL/min.
Validation of this HPLC method was performed according to
the Guidance for Industry for Bioanalytical Method Valida-
tion (US FDA, 2001). The calibration curves were obtained
by plotting the ratio of the alendronate peak area to the IS
peak area against the alendronate concentration in ng/mL.
The calibration curve was constructed over the range of 5-
100 ng/mL for plasma and 5-200 ng/mL for urine. The lower
limit  of  quantification  (LLOQ)  was  determined  for  both
plasma and urine.
To assess the accuracy and precision, three different
levels of plasma quality control (QC) samples of (15, 40, 80 ng/
mL) and urine QC samples (5, 15, 40 ng/mL) were prepared.
The  intraday  accuracy  and  precision  were  determined  by
repeated analyses of the QC samples on the same day (N > 5).
The  interday  accuracy  and  precision  were  determined  by
repeated analyses of the QC samples on 5 different days. Re-
covery was determined by comparing the peak area of the
alendronate (80 and 40 ng/mL in the plasma and urine, res-
pectively) and pamidronate (200 ng/mL) after extraction and
derivatization  to  that  of  each  analyte  obtained  in  the  un-
extracted standard solution.
The stability of alendronate in plasma samples was
evaluated at 2 predetermined concentrations. Human plasma
samples spiked with alendronate at 50 and 500 ng/mL were
stored at -20°C. At least 3 aliquots of each concentration were
analyzed, and the obtained concentrations were compared
to the mean of the back-calculated values for the standards
from the first day of long-term stability testing.
2.6 Pharmacokinetic analysis
Pharmacokinetic parameters were analyzed by the
non-compartmental method using WinNonlin (Pharsight Cor-
poration, California). The area under the plasma concentra-
tion-time curve (AUC) was calculated using the trapezoidal
rule and extrapolated to infinity. The elimination half-life (t1/2)
was calculated using the relationship t1/2 = ln2/k, where k was
the elimination rate constant obtained from WinNonlin. Uri-
nary excretion was evaluated as the total (cumulative) amount
excreted in the urine (U0-10) and maximum excretion rate (Rmax).
Data were reported as mean and standard deviation.
3. Results
Seven healthy males were recruited in the study. De-
mographic data (mean ± SD) of the participants are shown in
Table 1: age 22.3±2.5 years, height 171.6±4.7 (range 168-181)
cm, weight 63.1±9 (range 52-74) kg, and BMI 21.4±3.0 kg/m
2.
All participants had normal GFR. Linearity can be described
by y = 0.0050 (±0.0003)x - 0.023 (± 0.0078) (r
2 = 0.9986) at
5-100 ng/mL plasma;  and y = 0.0215 (±0.00625)x - 0.0944
(±0.0821) (r
2 = 0.9980) at 5-200 ng/mL urine. The lower limits
of quantification (LLOQ) were 18.34 ng/mL (88±9.50 % accu-
racy) is in plasma, and 18.33 ng/mL (109.9±16.0 % accuracy)
in urine. The LLOQ in plasma was higher than the previously
reported values 1 and 2 ng/mL plasma (Yun et al., 2006 and
Rhim et al., 2009), but LLOQ in urine was slightly lower than
previously reported values by Kang et al., 2006 (25 ng/mL).
The precision in the plasma ranged from 6.38-18.6%
(intraday) and 9.93-13.2% (interday). The precision in the
Table 1. Demographic data of study participants
Participants Gender Age Weight Height BMI GFR
(year) (kg) (cm) (mL/min/1.73 m
2)
1 M 27 74 168 26.22 106.25
2 M 21 53 168 18.78 101.33
3 M 22 72 174 23.78 111.66
4 M 23 64 181 19.54 93.99
5 M 23 69 171 23.60 101.21
6 M 19 52 168 18.42 101.74
7 M 21 58 171 19.84 98.70
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urine ranged from 1.54-16.2% (intraday) and 2.58-24.3%
(interday).  The recovery of alendronate from the plasma and
urine samples were 80.75±4.80% and 109.1 ± 9.04%, respec-
tively. Alendronate remaining in plasma after 45 days storage
at -20°C were 97.0±22.0% and 97.7±18.3% of the original
amount at 50 and 150 ng/mL, respectively. These validation
data indicated that the analytical method had good linearity,
sensitivity, accuracy, and precision, and therefore was appro-
priate for pharmacokinetic study.
Plasma alendronate concentration-time profiles from
seven patients are shown in Figure 1. Alendronate was readily
absorbed into the plasma with a measurable concentration at
the first sampling time (0.25 h) in all volunteers. A maximum
plasma concentration (56.6±11.8 ng/mL) was attained at 1.29
±0.39 h with terminal half life (t1/2) of 3.43±2.24 h (Table 2).
The areas under the plasma-time curve AUC0-10 and  1 AUC 
were 132.40±46.9 and 150.9±52.7 (ng×h/mL), respectively,
which extrapolated to an AUC of approximately 11.52±12.1%
of the total AUC.
Urinary excretion data, summarized in Table 3, revealed
maximum excretion rate (Rmax) during the first interval (0-2 h)
were found in most of the participants. Total amount excreted
in 10 h (U0-10) of 578.6±309 µg, and maximum excretion rate
(Rmax)  of  143.32±72.8  µg/h,  were  several  fold  higher  than
previously reported values (Kang et al., 2006). Plot of excre-
tion rate of alendronate versus the mid-point of the interval
after a dose of Fosamax Plus
® tablet (70 mg) was shown in
Figure  2.  When  natural  log  of  excretion  rate  was  plotted
against time of mid point, the linear relationship was obtained
(Figure 3). The terminal slope of this line (representing this
elimination rate constant, k) was 0.382±0.056 h
-1, and the
corresponding half life calculated from k was 1.844±0.272 h.
3.1 Tolerability
No  adverse  event  was  observed  during  the  study
period or one week after study. Thus, the combined tablet
was well tolerated in these healthy male volunteers.
4. Discussion
Total amount excreted in urine obtained in our study
(0.578±0.31 mg) was consistent with 24-h excreted in urine
(U0-24) of 0.59±0.38 mg reported by Roldan (Roldan et al.,
2005). However, the inconsistency between as urinary data
and these of other studies was noted. Among the previous
related studies, only the study by Denker had employed the
same product as our study (Denker et al., 2010). Their study,
however, has shown lower excretion data (median U0-36 209.4
µg; range 3617.7, 11.3 µg) than our finding (U0-10 578.6±309
Figure 1. Plasma concentration-time profiles from healthy volun-
teers after oral administration of single combined tablet
of Alendronate sodium 70 mg/Vitamin D3 (N = 7)
Table 2. Pharmacokinetic parameters in healthy volunteers
after oral administration of a single combined tablet
of Alendronate sodium 70 mg/Vitamin D3 (N = 7)
          Parameters Mean ± SD (N = 7)
Cmax  (ng/mL)   56.59 ± 11.8
Tmax  (h)      1.29 ± 0.39
AUC0-10  (ng.h/mL) 132.40 ± 46.9
1 AUC   (ng.h/mL) 150.98 ± 52.7
k  (h
-1)     0.28 ± 0.14
t1/2  (h)     3.43 ± 2.24
Cl/F  (L/h)     510.4 ± 162.0
Vd/F (L)     2,496 ± 1,814
Table 3. Urinary excretion data of alendronate in healthy volunteers after oral administration of  70 mg
alendronate tablet (Fosamax
®)  and combined Alendronate/Vitamin D3 tablet (Fosamax Plus
®)
Current study results
                    Urinary parameters
Fosamax Plus
® Fosamax
®
(N = 7)
a (N=5)
b p-value
Urine volume (mL)    979.71 ± 269.5   984.0 ± 550.2 0.493 -
Maximum excretion rate [Rmax]  (µg/h) 143.32 ± 72.8 52.842 ± 14.56 0.011 65.67 ± 20.8
Total amount excrete [U0-t]  (µg)   578.59 ± 308.9 178.69 ± 51.16 0.002 198.4 ± 81.2
Tmax  (h)     1.286 ± 0.756   1.400 ± 0.894 0.408   0.93 ± 0.59
a: 10 h urine collection
b: 12 h urine collection
Kang et al.
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µg). Two differences  between our study and that of Denker
et al. were noticed. Firstly, the fasting period post dosing
(4 h) in our study was longer than that in the study by Denker
(2 h). Owning to the low oral bioavailability and its ability to
form complexes with multivalent cations, timing of meals can
affect absorption of alendronate (Porras et al., 1999). Drug
administration  either  immediately  or  2  h  after  breakfast
lowered bioavailability by about 85-90% (Gertz et al., 1995).
We expected minimal food effects in our study by using a
4-h fasting period, while a shorter fasting period could con-
tribute to the result discrepancy. Secondly, both males and
females  were  included  in  the  study  by  Denker  while  only
males were enrolled in our study. A number of issues related to
gender differences are discussed herein. Since GI absorption
of alendronate occur mainly via the paracellular pathway, the
soluble alendronate should be available at the absorption site
long enough to maximize the absorption (Lin, 1996). There-
fore, an empty GI tract after drug administration is critical for
alendronate absorption and clinically recommended. Slower
gastric emptying in females than in males was reported (91.7 h
female vs. 44.8 h males) (Stephen et al., 1986; Gandhi et al.,
2004; Soldin and Mattison, 2009).  This was partly due to GI
motility inhibition by estrogen (Gandhi et al., 2004). Para-
cellular absorption of alendronate was postulated to occur at
the jejunum and duodenum (Lin, 1996), therefore, the slow
gastric emptying would diminish absorption. Oral bioavail-
ability of alendronate was 0.76% in postmenopausal women
(Porras et al., 1999). Under fasting condition, oral bioavail-
ability was 0.64 % in women after taking 5-70 mg alendronate,
and 0.59 % in men after taking 10 mg alendronate (Physician
Desk Reference). Thus, gender could lead to biological vari-
ability  that  affect  bioavailability  of  the  molecule  absorbed
via the intricate paracellular pathway and thus explain the
discordance of the results of the two studies.
In addition to the above addressed factors, body posi-
tion post dosing might affect alendronate absorption. Transit
time from mouth to stomach (mouth to stomach transit time,
MST)  was  examined  in  participants  in  standing  and  lying
position after alendronate administration (Acotto et al., 2012).
Results revealed longer MST in participants in lying position
compared to those in standing position post administration
(73.1s vs. 30.9 s, respectively; p <0.09) (Acotto et al., 2012).
Although no statistical significance obtained in this small
sample size, the results implied longer time a tablet traversing
from esophagus to stomach in persons in the lying position.
Thus, a recommendation for patients remaining upright after
drug administration would be prudent for therapeutic success
(Acotto et al., 2012). In our study, we have strictly followed
this specific instruction for drug administration. However,
additional information which can affect the study results, i.e.
participant’s  activity  post  administration,  urine  collection
procedures, had not been described in the study by Denker.
Thus, the disparity of the data from two studies could not be
simply ascribed.
In our study, plasma derived data, Tmax (1.29±0.39 h),
agreed well with urinary excretion data, Rmax (1.29±0.76 h).
Considering plasma parameters, larger Cmax, AUC, and t1/2
than previously reported values by Rhim were obtained. For
example, elimination rate constants (k) of 0.28 ± 0.14 h
-1
vs.0.37±1.58 h
-1, corresponding to t1/2 of 3.43±2.24 h vs.1.85±
0.44 (Rhim et al., 2009). Significant differences could not be
examined due to different drug product used.  However, t1/2
calculated from urinary excretion data (1.84 ± 0.27 h) in this
study was similar to those obtained from plasma data in other
previous studies. The discordance between plasma derived
k and urine derived k might be due to the multicompartment
nature of alendronate. This is evident from plasma time profile
of alendronate showing a biphasic decline after peak time
(Figure 1). Estimation of k from those 3-4 points after Tmax
might not reflect true elimination constant. Alendronate is
eliminated solely by renal excretion so that renal clearance
represents  systemic  clearance.  Excretion  data  can  provide
accurate elimination parameters during the first 12 h after
administration (Porras et al., 2009).
Taking account of urinary excretion data, increased
alendronate absorption after administration of combined
Alendronate/Vitamin D3 tablet was suggested. In this study,
Figure 2. Urinary  excretion  profile  of  Alendronate  from  healthy
volunteers after oral administration of single combined
tablet of Alendronate sodium 70 mg/Vitamin D3 (N = 7)
Figure 3. Urinary excretion rate (Ln) of Alendronate versus Mid
time  from  healthy  volunteers  after  oral  administration
of single combined tablet of Alendronate sodium 70 mg/
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we  have  conducted  a  preliminary  study  in  healthy  male
volunteers administering alendronate 70 mg without vitamin
D3. The result revealed data consistent with than previously
reported by Kang (Kang et al., 2006) (Table 3). In this preli-
minary study, the amount of alendronate presented in 12 h
urine and Rmax were reduced compared to those values from
alendronate plus vitamin D3 administration (Table 3). Signifi-
cant increase calcium absorption has been demonstrated in
a randomized controlled trial including 56 postmenopausal
women administered combined Alendronate/Vitamin D3 tablet
(Shapes et al., 2011). An in vitro study has shown the stimu-
lation of paracellular calcium influx by vitamin D3 and its
analogs in Caco-2 cell culture (Chirayath et al., 1998). This
was associated with a reduction of transepithelial electric
resistance (TEER) by about 50% in the presence of 1a,25-
dihydroxyvitamin D3 at 10
-5 to 10
-3 mM (Chirayath et al.,1998).
Since alendronate binds strongly to Ca
2+, greater permeabi-
lity of Ca
2+ during reduced TEER might facilitate alendronate
traversing tight junctions of the intestinal epithelium. This
could partly contribute to the enhanced alendronate absorp-
tion in these healthy volunteers.
Since approximately 45% of the alendronate dose was
excreted  in  36  h,  and  54%  was  excreted  in  the  first  week
(Khan et al., 1997). Approximately 46% of the drug adminis-
tered was retained in the skeleton, which could be slowly
released from bone during elimination phase (Lin et al., 1996).
Because of high affinity to bone, alendronate plasma concen-
tration was quite low and undetectable after 8-10 h of oral
administration.  Therefore,  pharmacokinetics  data  derived
from plasma data were normally reported up to 7 h (Yun et al.,
2006a; Yun et al., 2006b; Rhim et al., 2009). Because plasma
concentrations after 10 h are undetectable, the data up to 10 h
was reported in our study. One drawback of the analytical
method presented here was high LLOQ in plasma analysis,
compared to the reported analytical method (1 ng/ml by Yun).
However, the method of determining LOD and LLOQ was not
clearly addressed in the study by Yun. Instrument is related
problems, such as detector (light source), analytical column,
could  be  the  resource  of  such  errors.  In  our  study,  initial
LLOQ was estimated from LOD + 10*SD, the predicted value
was then verified with spiked samples. While the accuracy
and precision were within the acceptable range of ±20 %, the
LLOQ was large due to the large SD.
For urine samples, LLOQ of 18 ng/mL was lower than
that reported by Kang (25 ng/mL) (Kang et al., 2006). Due to
the fact that a large amount of alendronate was excreted in
urine in 10 h, the sensitivity of the method was sufficient in
determining alendronate concentration in urine. Since only
1 ml of urine sample was required for each analysis, the sensi-
tivity for the analytical method can be improved by increasing
urine volume.
We  attempted  to  use  plasma  and  urine  data  in
examining pharmacokinetics of alendronate from combined
Alendronate/Vitamin D3. No interference from vitamin D3 was
found in the analysis of either plasma or urine samples, con-
firming specificity of the analytical method. The sensitivity of
the analytical method was adequate in determining amount of
alendronate in urine sample, while plasma levels determina-
tion was still challenging. Urinary excretion data, which is the
pharmacologically relevant parameter, was demonstrated in
this study and suggested enhanced absorption of alendro-
nate in these volunteers. Finally, since the parameters from
this study were obtained from healthy young volunteers,
other considerations should be taken into account before
drawing inferences from the data to an actual clinical situa-
tion in a particular separate population, such as postmeno-
pausal women.
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